» Articles » PMID: 35700043

Myeloid FoxO1 Depletion Attenuates Hepatic Inflammation and Prevents Nonalcoholic Steatohepatitis

Abstract

Hepatic inflammation is culpable for the evolution of asymptomatic steatosis to nonalcoholic steatohepatitis (NASH). Hepatic inflammation results from abnormal macrophage activation. We found that FoxO1 links overnutrition to hepatic inflammation by regulating macrophage polarization and activation. FoxO1 was upregulated in hepatic macrophages, correlating with hepatic inflammation, steatosis, and fibrosis in mice and patients with NASH. Myeloid cell conditional FoxO1 knockout skewed macrophage polarization from proinflammatory M1 to the antiinflammatory M2 phenotype, accompanied by a reduction in macrophage infiltration in liver. These effects mitigated overnutrition-induced hepatic inflammation and insulin resistance, contributing to improved hepatic metabolism and increased energy expenditure in myeloid cell FoxO1-knockout mice on a high-fat diet. When fed a NASH-inducing diet, myeloid cell FoxO1-knockout mice were protected from developing NASH, culminating in a reduction in hepatic inflammation, steatosis, and fibrosis. Mechanistically, FoxO1 counteracts Stat6 to skew macrophage polarization from M2 toward the M1 signature to perpetuate hepatic inflammation in NASH. FoxO1 appears to be a pivotal mediator of macrophage activation in response to overnutrition and a therapeutic target for ameliorating hepatic inflammation to stem the disease progression from benign steatosis to NASH.

Citing Articles

Enhancing the Therapeutic Efficacy of Berberine and Quercetin Through Salt Formulation for Liver Fibrosis Treatment.

Cheng Y, Yu H, Yang S, Tian X, Zhao M, Ren L Int J Mol Sci. 2025; 26(5).

PMID: 40076811 PMC: 11899775. DOI: 10.3390/ijms26052193.


Origin, Function, and Implications of Intestinal and Hepatic Macrophages in the Pathogenesis of Alcohol-Associated Liver Disease.

Hu Y, Schnabl B, Starkel P Cells. 2025; 14(3).

PMID: 39936998 PMC: 11816606. DOI: 10.3390/cells14030207.


The role of immunity in insulin resistance in patients with polycystic ovary syndrome.

Zhang Q, Yang Z, Ou X, Zhang M, Qin X, Wu G Front Endocrinol (Lausanne). 2025; 15:1464561.

PMID: 39911236 PMC: 11797073. DOI: 10.3389/fendo.2024.1464561.


Identification of biomarkers associated with coronary artery disease and non-alcoholic fatty liver disease by bioinformatics analysis and machine learning.

Lu C, Han M, Ma Q, Ying L, Zhang Y Sci Rep. 2025; 15(1):3557.

PMID: 39875572 PMC: 11775188. DOI: 10.1038/s41598-025-87923-7.


Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy.

Tian Y, Ni Y, Zhang T, Cao Y, Zhou M, Zhao C Front Cell Dev Biol. 2024; 12:1444198.

PMID: 39300994 PMC: 11410645. DOI: 10.3389/fcell.2024.1444198.


References
1.
Goudriaan J, Tacken P, Dahlmans V, Gijbels M, van Dijk K, Havekes L . Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol. 2001; 21(9):1488-93. DOI: 10.1161/hq0901.095147. View

2.
Rajamoorthi A, Arias N, Basta J, Lee R, Baldan A . Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate. J Lipid Res. 2017; 58(11):2127-2138. PMC: 5665668. DOI: 10.1194/jlr.M077941. View

3.
Shimobayashi M, Albert V, Woelnerhanssen B, Frei I, Weissenberger D, Meyer-Gerspach A . Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018; 128(4):1538-1550. PMC: 5873875. DOI: 10.1172/JCI96139. View

4.
Wang X, Zheng Z, Caviglia J, Corey K, Herfel T, Cai B . Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2017; 24(6):848-862. PMC: 5226184. DOI: 10.1016/j.cmet.2016.09.016. View

5.
Langlet F, Haeusler R, Linden D, Ericson E, Norris T, Johansson A . Selective Inhibition of FOXO1 Activator/Repressor Balance Modulates Hepatic Glucose Handling. Cell. 2017; 171(4):824-835.e18. PMC: 5687849. DOI: 10.1016/j.cell.2017.09.045. View